This Claim is supported by the quoted statements and papers below.
|Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics. ||16214597 ||2. Trialists, Cholesterol Treatment. "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins." The Lancet 366.9493 (2005): 1267-1278.|
|Clinical trials in patients with and without coronary heart disease and with and without high cholesterol have demonstrated consistently that statins reduce the relative risk of major coronary events by approximately 30% and produce a greater absolute benefit in patients with higher baseline risk. ||10637210 ||Maron, David J., Sergio Fazio, and MacRae F. Linton. "Current perspectives on statins." Circulation 101.2 (2000): 207-213.|
|Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17%. ||15125495 ||Law, Malcolm R., Nicholas J. Wald, and A. R. Rudnicka. "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis." Bmj 326.7404 (2003): 1423.|